晚期卵巢癌新辅助化疗后微创间歇性减瘤术
基于美国国家癌症数据库2013至2018年IIIC或IV期上皮性卵巢癌接受新辅助化疗后间歇性减瘤术的患者,经倾向评分匹配比较微创手术与开腹手术,微创手术组总生存不劣于开腹手术且术后30天和90天死亡率、住院时间、残留病灶及额外减瘤操作均更低。
要点
- 微创间歇性减瘤术组中位总生存46.7个月,开腹组41.0个月,HR 0.86(95%CI 0.79-0.94)。
- 微创组5年生存概率38.3%,开腹组34.8%(p<0.01)。
- 微创组30天死亡率0.3% vs 开腹组0.7%(p=0.04),90天死亡率1.4% vs 2.5%(p=0.01)。
核心结论
- 接受微创间歇性减瘤术的患者与开腹手术相比总生存相似且发病率降低。
研究设计与样本
- 利用美国国家癌症数据库识别2013至2018年诊断为IIIC或IV期上皮性卵巢癌、接受新辅助化疗和间歇性减瘤术的患者,共7897例符合纳入标准,其中2021例(25.6%)接受微创手术。
- 采用倾向评分匹配比较微创手术与开腹手术用于间歇性减瘤术,主要结局为总生存,次要结局包括5年生存、术后30天和90天死亡率、手术范围、残留病灶、住院时间、手术中转和计划外再入院。
- 使用Kaplan-Meier法和Cox回归评估治疗方式与总生存的关联,并对未测量混杂因素的影响进行敏感性分析。
主要发现
- 研究期间接受微创手术的比例从20.3%上升至29.0%。
- 倾向评分匹配后,微创组中位总生存46.7个月 vs 开腹组41.0个月,HR 0.86(95%CI 0.79-0.94)。
- 微创组5年生存概率38.3% vs 开腹组34.8%(p<0.01)。
- 微创组30天死亡率0.3% vs 开腹组0.7%(p=0.04),90天死亡率1.4% vs 2.5%(p=0.01),住院时间中位数3天 vs 5天(p<0.01)。
- 微创组残留病灶23.9% vs 开腹组26.7%(p<0.01),额外细胞减灭操作59.3% vs 70.8%(p<0.01),计划外再入院率2.7% vs 3.1%(p=0.39)无显著差异。
临床怎么用
- 原文结论指出,接受微创间歇性减瘤术的患者与开腹手术相比总生存相似且发病率降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assess outcomes of interval debulking surgery (IDS) after neoadjuvant chemotherapy via minimally invasive surgery (MIS) compared with laparotomy in patients with advanced epithelial ovarian cancer. METHODS: Patients diagnosed with stage IIIC or IV epithelial ovarian cancer between 2013 and 2018 who received neoadjuvant chemotherapy and IDS were identified in the National Cancer Database. Primary outcome was overall survival. Secondary outcomes were 5-year survival, 30- and 90-day postoperative mortality, extent of surgery, residual disease, hospitalization duration, surgical conversions, and unplanned readmissions. Propensity score matching was used to compare MIS and laparotomy for IDS. Association of treatment approach with overall survival was assessed using Kaplan-Meier method and Cox regression. Sensitivity analysis was conducted for effect of unmeasured confounders. RESULTS: A total of 7897 patients met inclusion criteria; 2021 (25.6%) underwent MIS. Percentage undergoing MIS increased from 20.3%-29.0% over the study period. After propensity score matching, median overall survival was 46.7 months in the MIS group versus 41.0 months in the laparotomy group [hazard ratio (HR) 0.86 (95%CI 0.79-0.94)]. Five-year survival probability was higher in MIS versus laparotomy (38.3% vs 34.8%, p < 0.01). There was lower 30- and 90-day mortality (0.3% vs 0.7% [p = 0.04] and 1.4% vs 2.5% [p = 0.01], respectively), shorter length of stay (median 3 vs 5 days, p < 0.01), lower residual disease (23.9% vs 26.7%, p < 0.01), and lower additional cytoreductive procedures (59.3% vs 70.8%, p < 0.01) in MIS compared to laparotomy, with similar rates of unplanned readmission (2.7% vs 3.1%, p = 0.39). CONCLUSIONS: Patients who undergo IDS by MIS have similar overall survival and decreased morbidity compared with laparotomy.
引用
- Jorgensen K, Melamed A, Wu CF, et al. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy. Gynecol Oncol. 2023. PMID: 36977622. doi:10.1016/j.ygyno.2023.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。